title: Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts.
abstract: Allogeneic stem cell transplantation (allo-SCT) remains an option for patients who have disease progression post-autologous stem cell transplantation (ASCT) or who would not be eligible to ASCT for relapsed diffuse large B-cell lymphoma. Data with myeloablative or non-myeloablative allo-SCT demonstrate that allografts are safe and feasible with potential benefits including lack of tumour cell contamination and possible graft-versus-lymphoma (GVLY) effect although limited by high non-relapse mortality (NRM). However, the benefit of GVLY effect may be minimal or minimized by NRM. The current role of allo-SCT in DLBCL remains to be defined by prospective randomized controlled trials.
authors.affiliation: Princess Margaret Cancer Center, Department of Medicine, University of Toronto, Canada.
authors.forename: Jieun
authors.initials: J
authors.lastname: Uhm
authors.forename: John
authors.initials: J
authors.lastname: Kuruvilla
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000601:surgery* / Q000628:therapy; D014184:Transplantation, Homologous; D016896:Treatment Outcome